RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:The share prices says what the market thinksThis is your interpretetation. I also have my own interpretation. The fact here is that the company doesn' t make it clear what they are doing and planning on doing and when. If they would put down a plan on paper, people could choose to agree with it or not by selling or holding. Phil would also not have to have a chat with several hundred investors asking the same thing over and over again.
MoneyMouth wrote:
Well I think within a month or so, the new hire from today will likely be able to answer your questions regarding thyroid and likely other clinical trials as that is what his expertise is. Additionally, I think it is quite clear that Hemo is on the back burner right now. If you read the MD&A, you'll see a brief discussion on how two pharmaceutical collaborations took place, both with stem-cell derived technologies, one of which was with locally immune protected stem cells. Sure we may not know the exact results from those pre-clinical tests, but we know they took place and that my friend is progress. As far as Hemophillia goes, that stuff from last year was the result of multiple research teams collaborating together. From what I can tell, Sernova simply supplied the pouch, others supplied the cells. The most probable cause for any lack of new progress on that front is likely a result of the difficulty of coordinating such an effort again. Sernova would likely have to buy the technology from whichever team supplied the cells for Sernova to begin work on an independent clinical trial. I can see why this is not a key focus right now. Dr. Toleikis has said multiple times now that his focus is on securing licensing deals. It is likely that any clinical trial for diabetes regarding stem-cells or immune-protected cells would come after the cell supplier agreed to license and probably help fund that clinical trial. This is also likely why Sernova needed to raise funds. Those licensing deals likely include discussions on how they will bring the product to a clinical trial. The licensee likely would want Sernovs to pitch in on those costs, and having a big ol bank account tells those potential licensee's that they are capable of doing so. Again this is another very key factor in why todays new hire is excellent. He will be able to communicate with these pharma companies and layout an actual plan so that licensee's can have an acurate estimate on what will happen following their investment. Its pretty obvious that Sernova will not be letting collaborators enter the clinic with the device for free, and will not be letting them do it alone. It will be a joint venture which bodes well for the relationship that will develop. So yeah, I think Sernova might be in a bit of a mexican standoff because they don't want to develop these technolgies alone anymore, which explains the stall on progress. I hope you can see the benefits to this approach, i.e. a larger more diverse team, increased funding, additional expertise - All of which are significantly cheaper than Sernova trying to do it alone. Just look at the last 10 years if you wanna know what "Sernova lone-wolfing it" would look like